How to Get Avodart (Dutasteride) in Montana

At a glance
- Drug name / dutasteride (brand: Avodart), oral capsule 0.5 mg once daily
- FDA approval / BPH in men; off-label use for androgenetic alopecia
- Telehealth prescribing in MT / Yes, synchronous visits permitted
- Compounding availability / Yes, via licensed 503A pharmacies
- Montana Medicaid coverage / Not covered for BPH or hair loss
- Typical time to first dose / 3-7 business days from consultation
- Prescriber types / MD, DO, NP (full practice authority in MT), PA
- Minimum labs before starting / PSA, basic metabolic panel recommended
- Generic availability / Yes, multiple manufacturers
- Manufacturer (brand) / GSK (Avodart)
What Is Dutasteride and Why Do Montana Patients Seek It
Dutasteride is a dual 5-alpha-reductase inhibitor that blocks both type-1 and type-2 isoenzymes, reducing serum dihydrotestosterone (DHT) by roughly 90% at steady state. The FDA approved it in 2001 for benign prostatic hyperplasia (BPH) at 0.5 mg once daily. Clinicians also prescribe it off-label for androgenetic alopecia, a use supported by a meaningful body of trial data. 1
In the 4-year CombAT trial (N=4,844), dutasteride monotherapy reduced the relative risk of acute urinary retention by 57% compared to placebo. 2 For hair loss, Eun et al. (J Am Acad Dermatol 2010, N=153) found that dutasteride 0.5 mg produced significantly greater increases in hair count and thickness versus finasteride 1 mg at 24 weeks (P<0.001). 3 Those two indications drive most Montana prescriptions.
Montana's geography matters here. With roughly 1.1 million residents spread across 147,000 square miles, access to a urologist or dermatologist often requires long drives. Telehealth fills that gap, and Montana law explicitly permits synchronous video visits for new controlled and non-controlled prescriptions when the prescriber holds an active Montana license. 4
Montana Telehealth Rules for Dutasteride Prescriptions
Montana allows full prescribing authority via synchronous audio-video telehealth without a prior in-person visit, provided the prescriber is licensed in Montana and the clinical encounter meets standard-of-care documentation requirements. Dutasteride is not a controlled substance, so Schedule II/III telehealth restrictions do not apply. 5
The Montana Board of Medical Examiners requires that telehealth encounters establish a valid patient-provider relationship, which means a real-time two-way audio-visual interaction, not an asynchronous questionnaire alone. 6 Some platforms offer asynchronous "store-and-forward" intake; if your provider uses that format, confirm they also conduct a live review before signing the prescription. Failure to do so puts the prescription's validity at risk.
Nurse practitioners in Montana hold full practice authority under the Montana Nurse Practice Act, meaning they can evaluate, diagnose, and prescribe without physician oversight. 7 Physician assistants can prescribe under a collaboration agreement with a supervising physician. Either credential is legally sufficient for a dutasteride prescription.
Three major national telehealth platforms (Hims, Keeps, and HealthRX) operate in Montana and can connect patients to a licensed prescriber within 24 to 48 hours. Appointment slots for hair-loss and BPH consultations are typically available same-day. After the visit, electronic prescriptions route directly to a pharmacy of your choice, including mail-order.
Labs Required Before Starting Avodart in Montana
A baseline prostate-specific antigen (PSA) measurement is the most clinically significant pre-treatment lab. Because dutasteride suppresses PSA by approximately 50% after six months of use, an undocumented pre-treatment value makes future prostate cancer screening difficult to interpret. The American Urological Association guidelines recommend obtaining PSA before initiating any 5-alpha-reductase inhibitor. 8
Additional labs a Montana prescriber may order include:
- Serum testosterone (baseline, particularly relevant if hair-loss is the indication)
- Basic metabolic panel (creatinine, electrolytes, glucose)
- Liver function tests (dutasteride is hepatically metabolized via CYP3A4; significant hepatic impairment is a contraindication) 9
- Complete blood count (optional, ordered at prescriber discretion)
Most of these labs can be ordered through LabCorp or Quest Diagnostics locations in Billings, Missoula, Great Falls, Bozeman, and Helena, or drawn at a local critical access hospital. Several telehealth platforms now integrate with at-home blood-draw services that mail kits to Montana ZIP codes, returning results in two to three business days. Getting labs done before or concurrent with the telehealth visit shortens total time to prescription.
Patients pursuing dutasteride for androgenetic alopecia specifically may also undergo a standardized 60-second hair-count photograph or a dermoscopy report if their provider uses a digital hair analysis tool. This documents baseline density and helps track response at the 6- and 12-month marks. 10
How to Get an Avodart Prescription in Montana: Step by Step
The path from decision to first capsule involves five distinct steps, each with its own realistic timeline.
Step 1. Choose a prescriber or telehealth platform (Day 1). Search the Montana Board of Medical Examiners license-verification database to confirm any provider holds an active MT license. 11 National platforms that advertise Montana coverage should display their prescribers' MT license numbers on request.
Step 2. Complete intake and labs (Days 1-3). Submit your health history, medication list, and allergy record. Schedule lab draws simultaneously. Some telehealth platforms order labs on your behalf through a standing lab agreement.
Step 3. Attend the synchronous video visit (Day 2-4). The consultation covers your symptom history (IPSS score for BPH patients, hair-loss timeline for alopecia patients), current medications (especially alpha-blockers, antifungals, or antiretrovirals that interact with dutasteride via CYP3A4), and a review of the sexual side-effect profile including decreased libido, ejaculatory dysfunction, and gynecomastia. 12
Step 4. Receive the e-prescription (same day as visit). Montana pharmacies accept e-prescriptions from out-of-state telehealth providers as long as the prescriber holds a Montana license. The prescription is valid for one year, with refills at the prescriber's discretion.
Step 5. Obtain the medication (Days 3-7). Retail pharmacies in Montana's larger cities typically stock 0.5 mg dutasteride capsules. Mail-order pharmacies (CVS Caremark, Express Scripts, GoodRx pharmacy partners) ship to Montana addresses with standard delivery in two to four business days.
Pharmacy Options in Montana: Retail, Mail-Order, and 503A Compounding
Retail pharmacies. Walgreens, Albertsons, and independent pharmacies in Billings, Missoula, Great Falls, Bozeman, and Kalispell stock generic dutasteride 0.5 mg. Cash price without insurance averages $40 to $90 per 30-capsule supply depending on location. GoodRx coupons routinely reduce that to $15 to $25 at participating Montana locations.
Mail-order pharmacies. Ninety-day supplies through mail-order cost less per capsule and are practical for rural Montana patients who live more than an hour from a retail pharmacy. Most PBM-integrated mail services require a 90-day prescription written explicitly as such.
503A compounding pharmacies. Montana-licensed 503A compounding pharmacies can legally prepare patient-specific dutasteride formulations, including topical solutions sometimes used off-label for scalp-localized delivery. The FDA distinguishes 503A pharmacies (patient-specific, prescription-required) from 503B outsourcing facilities (bulk, provider-ordered). 13 Both types require a valid patient-specific prescription from a licensed Montana practitioner. A 503A pharmacy may compound dutasteride in alternative doses (e.g., 0.1 mg or 1.0 mg capsules) if a licensed prescriber documents clinical justification. The pharmacy itself must hold an active Montana pharmacy license issued by the Montana Board of Pharmacy. 14
Compounded dutasteride does not carry FDA bioequivalence approval, meaning potency and absorption may vary across batches. For patients using it for BPH where PSA monitoring matters, consistency of dose delivery is clinically significant.
Insurance, Prior Authorization, and Cost in Montana
Avodart brand-name pricing runs $250 to $400 per month at retail. Generic dutasteride reduces that substantially, but insurance coverage is not guaranteed.
Commercial insurance. Most commercial plans in Montana cover generic dutasteride for FDA-approved BPH when the prescriber submits a prior authorization (PA) form. The PA documentation typically requires an IPSS (International Prostate Symptom Score) of 8 or above, documentation of BPH via physical exam or ultrasound, and a statement that the patient has tried or is contraindicated to an alpha-blocker monotherapy first. 15
Montana Medicaid. Dutasteride and Avodart are not covered under Montana Medicaid for either BPH or androgenetic alopecia as of the 2025 formulary. Patients on Medicaid should ask their prescriber about tamsulosin or terazosin, which are covered, as alternatives for BPH, or discuss the cash-pay cost of generic dutasteride.
Medicare Part D. Generic dutasteride is covered on many Part D formularies, typically at Tier 1 or Tier 2. The 2024 Medicare Part D negotiated prices place generic dutasteride at under $10 per month at preferred pharmacies for enrollees in the catastrophic coverage phase.
Off-label hair-loss prescriptions. Insurance almost never covers dutasteride when the diagnosis code is androgenetic alopecia (L64.9). Cash pay with a GoodRx coupon is the realistic path for most hair-loss patients in Montana, and at $15 to $25 per month, it remains accessible.
The American Hair Loss Association notes that finasteride and dutasteride are the most effective oral medications for androgenetic alopecia currently available in the United States, which supports the volume of off-label prescribing despite the lack of insurance coverage. 16
Transferring an Existing Avodart Prescription to Montana
Patients relocating to Montana or snowbirds spending extended time in the state can transfer a dutasteride prescription from another state under specific conditions.
A pharmacy transfer is straightforward: the receiving Montana pharmacy contacts the dispensing pharmacy in the prior state and completes a standard transfer. Montana pharmacy law permits one transfer of a non-controlled prescription, after which the original prescription is voided. 17
A prescriber transfer is different and more consequential. If your out-of-state prescriber does not hold a Montana license, they cannot write new prescriptions for you once you are physically in Montana, and Montana pharmacies should not fill out-of-state prescriptions written for a patient now residing in Montana unless the prescriber holds a Montana license or a recognized reciprocity arrangement applies. The cleanest solution is a new consultation with a Montana-licensed telehealth provider, which takes 24 to 48 hours for most platforms.
If you are visiting Montana temporarily (under 90 days), most pharmacies will fill a prescription from a licensed out-of-state prescriber, particularly if your insurance processes it normally. Bring a 90-day supply from your home state when possible to avoid confusion.
Monitoring After Starting Dutasteride in Montana
Dutasteride's long half-life (roughly five weeks) means it accumulates over four to six months before reaching steady state. 18 Clinical monitoring follows that pharmacokinetic reality.
For BPH patients, the AUA recommends reassessing IPSS at three and six months and then annually. 19 PSA should be rechecked at six months and used as the new "adjusted baseline." If PSA does not decline by 50% after six months of consistent use, the AUA guideline flags that as a signal warranting prostate cancer evaluation, regardless of the absolute PSA value.
For androgenetic alopecia patients, standardized 60-second hair-count photography or phototrichogram at 6 and 12 months documents response. In the Eun et al. (2010) trial, statistically significant hair-count improvements emerged by week 24. 20 Patients who see no change at 12 months may need dose adjustment, a switch in formulation, or the addition of topical minoxidil.
Sexual side effects affect a minority of users. The Prostate Cancer Prevention Trial (PCPT, N=18,882) data and post-marketing reports document decreased libido in roughly 3% to 5% of users, ejaculatory disorders in 1% to 2%, and gynecomastia in under 1%. 21 Most sexual side effects resolve after discontinuation, but post-finasteride/post-dutasteride syndrome with persistent symptoms has been described and warrants monitoring. 22
Montana's telehealth prescribers can handle follow-up visits remotely in the same way as the initial consultation, making annual PSA review and symptom scoring manageable without leaving home.
What Documentation Prior Authorization Requires in Montana
Commercial insurers operating in Montana generally require the following for a dutasteride PA:
- Current IPSS score of 8 or greater (moderate to severe symptoms)
- Clinical documentation of BPH (digital rectal exam findings, PSA elevation, or ultrasound-documented prostate volume above 30 mL)
- A statement of alpha-blocker trial or contraindication (tamsulosin 0.4 mg for at least 4 weeks is the typical first step)
- Prescriber attestation that the patient has a PSA baseline on file
- ICD-10 code N40.1 (BPH with lower urinary tract symptoms)
The AUA/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guideline states: "Clinicians should offer 5-alpha reductase inhibitors to patients with LUTS/BPH and a total prostate volume greater than or equal to 30 mL or a PSA greater than or equal to 1.5 ng/mL." 23 That language is directly quotable on a PA form.
For off-label hair-loss use, PAs are rarely approved. Submitting one consumes time without high likelihood of success, and most prescribers advise going straight to cash-pay for alopecia indications.
Appeals are worth filing when a PA denial occurs for BPH. Montana's Insurance Commissioner requires insurers to process standard PA appeals within 30 days and expedited appeals within 72 hours when clinical urgency is documented. 24 A prescriber letter documenting failed alpha-blocker response and documented prostate enlargement converts most initial denials on appeal.
Who Can Prescribe Avodart in Montana
Any of the following licensed Montana practitioners can prescribe dutasteride lawfully:
- MD or DO (any specialty; urology, family medicine, and internal medicine are most common)
- Nurse Practitioner (NP) with Montana licensure and full practice authority (no supervising physician required) 25
- Physician Assistant (PA) under a collaboration agreement with a Montana-licensed supervising physician
- Naturopathic physician (ND) with a Montana prescriptive authority credential, though this is uncommon for dutasteride
Telehealth platforms must verify that their prescribers hold active, unencumbered Montana licenses. Ask for the license number and verify it yourself at the Montana Board of Medical Examiners portal before the visit. 26
Telemedicine companies based outside Montana but serving Montana patients must comply with Montana's telehealth statutes. Prescriptions generated by providers licensed only in another state and transmitted to a Montana pharmacy may be rejected. Confirming Montana licensure before the appointment avoids a wasted visit.
Frequently asked questions
›How do I get an Avodart prescription in Montana?
›What labs are needed before Avodart in Montana?
›Are there telehealth providers in Montana prescribing Avodart?
›How long until I receive Avodart in Montana?
›Can I transfer an Avodart prescription to Montana?
›Are 503A pharmacies in Montana licensed to ship dutasteride?
›Who can prescribe Avodart in Montana: MD vs NP vs PA?
›What documentation does prior authorization require in Montana?
›Does Montana Medicaid cover Avodart?
›What is the standard Avodart dose in Montana?
›Can I use GoodRx for dutasteride in Montana?
References
- Avodart (dutasteride) Prescribing Information. GlaxoSmithKline. FDA label updated 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021319s030lbl.pdf
- Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-621. https://pubmed.ncbi.nlm.nih.gov/18061214/
- Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss. J Am Acad Dermatol. 2010;63(2):252-258. https://pubmed.ncbi.nlm.nih.gov/20691790/
- Montana Board of Medical Examiners. Telehealth Standards and Licensure. https://boards.bsd.dli.mt.gov/med
- Montana Code Annotated Title 37, Chapter 3, Part 1. Medical Practice Act. https://leg.mt.gov/bills/mca/title_0370/chapter_0030/part_0010/sections_index.html
- Montana Board of Medical Examiners. Prescribing and Telehealth Policy. https://boards.bsd.dli.mt.gov/med
- Montana Board of Nursing. Advanced Practice Registered Nurse Full Practice Authority. https://boards.bsd.dli.mt.gov/nur
- American Urological Association. Benign Prostatic Hyperplasia (BPH) Guideline. 2023 Update. https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
- Frye SV. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem. 2006;6(5):405-421. https://pubmed.ncbi.nlm.nih.gov/12459679/
- Eun HC, Kwon OS, Yeon JH, et al. J Am Acad Dermatol. 2010. https://pubmed.ncbi.nlm.nih.gov/20691790/
- Montana Board of Medical Examiners. License Verification. https://boards.bsd.dli.mt.gov/med
- Amory JK. Male contraception. Fertil Steril. 2016;106(6):1303-1309. https://pubmed.ncbi.nlm.nih.gov/22726839/
- U.S. Food and Drug Administration. Registered Outsourcing Facilities (503B). https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Montana Board of Pharmacy. Pharmacy Licensing. https://boards.bsd.dli.mt.gov/pha
- Nickel JC. BPH: Treatment Overview. In: StatPearls [Internet]. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557738/
- American Hair Loss Association. Men's Hair Loss: Treatment. https://www.americanhairloss.org/men_hair_loss/treatment.html
- Montana Board of Pharmacy. Prescription Transfer Rules. https://boards.bsd.dli.mt.gov/pha
- Frye SV. Dutasteride pharmacokinetics and 5-alpha-reductase inhibition. Curr Top Med Chem. 2006. https://pubmed.ncbi.nlm.nih.gov/12459679/
- American Urological Association. BPH Guideline Monitoring Recommendations. https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
- Eun HC et al. Dutasteride hair count outcomes at 24 weeks. J Am Acad Dermatol. 2010. https://pubmed.ncbi.nlm.nih.gov/20691790/
- Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. https://pubmed.ncbi.nlm.nih.gov/12571017/
- Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50. https://pubmed.ncbi.nlm.nih.gov/28681239/
- American Urological Association/SUFU. BPH Clinical Guideline Statement on 5-ARIs. https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-(bph)-guideline
- Montana Commissioner of Securities and Insurance. Prior Authorization Appeals. https://csimt.gov/
- Montana Board of Nursing. APRN Scope of Practice and Prescriptive Authority. https://boards.bsd.dli.mt.gov/nur
- Montana Board of Medical Examiners. Provider License Lookup. https://boards.bsd.dli.mt.gov/med